^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CXCR4 positive

i
Other names: CXCR4, CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R, Chemokine (C-X-C motif) receptor 4
Entrez ID:
Related biomarkers:
2ms
Yigong Powder regulates CXCL12/CXCR4 signaling to reduce glutamate release and prevent cognitive decline in mouse model of aging (PubMed, Zhongguo Zhong Yao Za Zhi)
Forty KM mice were randomized into control, model, donepezil(1.5 mg·kg~(-1)), and high-dose(7.5 g·kg~(-1)) and low-dose(3.75 g·kg~(-1)) Yigong Powder groups...This study showed that the preventive administration of Yigong Powder can ameliorate the learning and memory decline of the D-galactose-induced aging mice by regulating the immune function of the spleen and the CXCL12/CXCR4 signaling in the brain to reduce glutamate release. However, the mechanism of Yigong San in preventing and treating dementia via regulating spleen and stomach function remains to be studied.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • GFAP (Glial Fibrillary Acidic Protein)
|
CXCR4 positive
4ms
CXCR4-directed PET/CT with [ Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology. (PubMed, Eur J Nucl Med Mol Imaging)
In a whole-body tumor read-out, a substantial portion of prevalent solid tumors demonstrated increased and uniform [ Ga]Ga-pentixafor uptake, along with high image contrast. We also observed a respective link between in- and ex-vivo CXCR4 expression, suggesting high specificity of the PET agent. Last, a fraction of patients with [ Ga]Ga-pentixafor-positive tumor burden were rendered potentially suitable for CXCR4-directed therapy.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCL8 expression • CXCR4 expression • CXCR4 positive
6ms
A Multimodal Analysis Of Glioblastoma Reveals The Potential Of Cxcr7-Cxcl12 In Gbm Cells Sensitizes Gbm To Immune Checkpoint Blockade Therapy (EANO 2023)
Among the secretory components, CXCL12, also known as stromal cell-derived factor 1 was accumulated during GBM progression and upregulated in temozolomide (TMZ)-resistant GBM cells compared with parental GBM cell lines... In accordance with the multimodal analysis, GBM regulated the accumulation of CXCL12 via silencing CXCR7 in GBM cells. The CXCR7-CXCL12 axis confers the immunosuppression by up-regulating PD-L1 in GAMs. Our study suggested that CXCR7 activation treatment alone or combined with an immune checkpoint inhibitor may be a potential strategy for the treatment of GBM.
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL6 (Interleukin 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • ACKR3 (Atypical Chemokine Receptor 3)
|
PD-L1 expression • CXCR4 positive
|
temozolomide
8ms
Evaluation of the influence of the C-X-C motif chemokine ligand 12 / C-X-C chemokine receptor 4 axis on canine mammary gland tumor cell migration. (PubMed, J Vet Med Sci)
This influence was canceled by pre-treatment with a CXCR4 antagonist. The results of our study suggest that the CXCL12/CXCR4 axis may be associated with the migration of canine MGT.
Journal • Tumor cell
|
CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCL12 expression • CXCR4 positive
9ms
Molecular mechanism of miRNA-23a in sepsis-induced lung injury. (PubMed, Am J Transl Res)
miR-23a can significantly alleviate sepsis-induced lung injury in CLP-induced septic mice and LPS-stimulated cell lines by suppressing NLRP3 inflammasome activation and inflammatory response, while promoting the CXCR4/PTEN/PI3K/AKT pathway.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • MIR23A (MicroRNA 23a) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
CXCR4 positive • miR-23a expression
1year
Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. (PubMed, Int J Cancer)
Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK CXCR4 CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis-directed radiotherapy.
Journal • Circulating tumor cells • Tumor cell
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCL2 (Chemokine (C-C motif) ligand 2)
|
CXCR4 expression • CXCR4 positive
|
CELLSEARCH®
1year
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures. (PubMed, Cancers (Basel))
(4) CXCR4- and FAP-directed PET imaging could provide a non-invasive decision aid for entity-agnostic treatment of microenvironment in solid malignancies. Moreover, this machine learning workflow can easily be transferred towards other theranostic targets.
Journal • Pan tumor • Machine learning
|
CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • FAP (Fibroblast activation protein, alpha)
|
FAP expression • CXCR4 expression • CXCR4 positive • FAP overexpression
1year
Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients. (PubMed, Cancers (Basel))
In extensive stage SCLC patients, the presence of ≥4 CXCR4-positive CTCs was associated with shorter OS (p = 0.041, HR = 5.01). Consequently, JUNB and CXCR4 were expressed in CTCs from lung cancer patients, and associated with patients' survival, underlying their key role in tumor progression.
Journal • Circulating tumor cells • Tumor cell
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
|
CXCR4 expression • CXCR4 positive
over1year
Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma (ASH 2022)
We present a case study of a RRMM patient who experienced pseudoprogression twice during his course of disease treatment that included BCMA CAR T cells Idecabtagene vicleucel and GPRC5DxCD3 bispecific antibody talquetamab. We present two educating episodes of pseudoprogression in one patient following immune oncology drugs in MM. While one event was transient and self-limiting, the pulmonary manifestations were similar to sarcoidosis and required treatment with steroids.
CAR T-Cell Therapy • IO biomarker
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD4 (CD4 Molecule) • CCL20 (C-C Motif Chemokine Ligand 20) • TBX21 (T-Box Transcription Factor 21) • IL17A (Interleukin 17A) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CCR6 (C-C Motif Chemokine Receptor 6) • KLRB1 (Killer Cell Lectin Like Receptor B1)
|
CXCR4 positive • CD4 positive
|
Abecma (idecabtagene vicleucel) • Talvey (talquetamab-tgvs)
over1year
Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma. (PubMed, Expert Rev Hematol)
The incidence of extramedullary lesions in CXCR4-negative patients increased significantly compared with CXCR4-positive patients. Plasma cells that reduce CXCR4 expression have poor prognosis and increase the incidence of extramedullary lesions.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 expression • CXCR4 positive
over1year
Imaging Aldosterone-Producing Adrenocortical Carcinoma With 68Ga-Pentixafor PET/CT. (PubMed, Clin Nucl Med)
Recently, 68Ga-pentixafor has been reported as a potential PET imaging agent for CXCR4-positive tumors and inflammatory lesions, including adrenocortical lesions. We report a case of primary aldosteronism due to adrenocortical carcinoma with intense 68Ga-pentixafor activity on PET/CT.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 positive
almost2years
EFFECT OF TRANSPLANTED CD184-POSITIVE CELLS (WITH EXPRESSION CXCR4) FOR A LONG SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA – ONE CENTER PROSPECTIVE STUDY. (EHA 2022)
Conditioning regimen was Melphalan...Twenty-seven pts died including 19 pts due to disease progression.  The median OS was 7.8 years. In the study group a statistically significant correlation was found between OS, PFS and the number of CD184+ cells. In the context of OS and PFS, number of CD184+ cells was found to have a negative impact (correlation coefficient R = -0.32, p=0.0261, and correlation coefficient R = -0.41, p=0.0039 for OS and PFS retrospectively).  As OS and PFS increased, the number of CD184+ cells decreased. Conclusion The number of CD184+ cells could have a negative effect on both OS and PFS in multiple myeloma patients.
Clinical
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 expression • CXCR4 positive
|
melphalan
almost2years
High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy. (PubMed, BMC Cancer)
• We observed a significant association between high pCXCR4/CXCR4 TIC ratio and better RFS in primary cancer biopsies, especially during the early postoperative follow-up and independent of known risk factors for recurrence. • High CXCR4 tumor expression in recurrent HGSOC biopsies might be indicative for sensitivity to chemotherapy. We found evidence that at the beginning of the disease (early follow-up) the role of the immune response seems to be the most crucial factor for progression. On the other hand in recurrent/progressive disease the biology of the tumor itself becomes more important for prognosis. • We explored for the first time the predictive and prognostic role of pCXCR4/CXCR4 TIC ratio in high-grade serous ovarian cancer.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCR4 expression • CXCR4 positive
2years
An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications. (PubMed, Pharmaceutics)
This study further confirms the applicability of PAMAM dendrimers for imaging and therapeutic applications. It also emphasizes careful consideration of image acquisition and/or treatment times when designing dendritic nanoplatforms for tumor targeting.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCR4 expression • CXCR4 positive
2years
Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [Ga]Ga-PentixaFor PET/CT. (PubMed, Mol Imaging Biol)
In patients with solid tumors imaged with [Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 positive
2years
Tumor microenvironment (TME) is more suppressive in hepatocellular carcinoma (HCC) than in colorectal cancer liver metastasis (CRLM): CXCR4 antagonism as strategy to revert T regulatory cells (Tregs) suppressive activity (AACR 2022)
These data suggest a more suppressive TME in HCC compared to CRLM and highlighted CXCR4 antagonism as a potential strategy to overcome Tregs-mediated TME immunosuppressive function in HCC and CRLM patients.
PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • IL15 (Interleukin 15)
|
PD-1 expression • CXCR4 positive
over2years
Stem Cell Markers CXCR-4 and CD133 Predict Aggressive Phenotype and Their Double Positivity Indicates Poor Prognosis of Oral Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
We discovered, for the first time, that patients with expression of both CXCR-4 and CD133 have a lower survival rate, and CXCR-4+/CD133+, as well as CXCR-4+/PKC-δ+ double positivity, can be utilized to predict poor prognosis. CXCR-4, PKC-δ and CD133 might regulate aggressiveness and invasion of oral cancer cells.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CD33 positive • CD133 expression • CXCR4 expression • CXCR4 positive
over2years
Investigation of spleen CXCR4 expression by [68Ga] -Pentixafor PET in a cohort of 145 solid cancer patients (DGHO 2021)
Splenic CXCR4 expression as assessed by [68Ga] -Pentixafor PET was not associated with clinical outcomes of solid cancer patients. However, we demonstrate platelet and / or leucocyte counts to be positively associated with splenic CXCR4 expression in some solid cancer entities. This suggests that splenic CXCR4 expression could possibly be a marker for an activated state of spleen in response to tumor activity in some solid cancer entities.
Clinical
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 expression • CXCR4 positive
over2years
Preclinical Evaluation of [Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma. (PubMed, Mol Pharm)
We developed a copper-64 (t = 12.7 h, 19% beta) labeling route of NOTA-CP01 derived from LY2510924, a cyclopeptide-based CXCR4 potent antagonist, in an attempt to noninvasively visualize CXCR4 expression in metastatic ESCC...The immunofluorescence and immunohistochemistry confirmed the positive expression of CXCR4 in the EC109 tumor and ESCC and metastatic lymph nodes of patients, respectively. We concluded that [Cu]NOTA-CP01 possessed a very high target engagement for CXCR4-positive ESCC and could be a potential candidate in the clinical detection of metastatic ESCC.
Preclinical • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 expression • CXCR4 positive
|
LY2510924
over2years
Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. (PubMed, J Control Release)
In addition, repeated T22-DITOX-H6 treatment (10 μg/dose per 10 doses, intravenously injected) in a disseminated AML mouse model (NSG mice intravenously injected with THP-1-Luci cells, n = 10 per group) potently blocks the dissemination of AML cells in bone marrow, spleen and liver of treated mice, without inducing toxicity in healthy tissues. In conclusion, our strategy of selectively ablating CXCR4 positive leukemic cells by administering the T22-DITOX-H6 nanoparticle could be a promising treatment, especially in patients undergoing AML relapse after chemotherapy, in which leukemic cells overexpress CXCR4.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 overexpression • CXCR4 expression • CXCR4 positive
almost3years
Association of SDF-1 Gene Polymorphism with Increased Risk of Acute Myeloid Leukemia Patients. (PubMed, Asian Pac J Cancer Prev)
SDF-1 dominant model had a higher risk to develop AML, and CXCR4 positive expression predicts poor prognosis in AML patients and it could represent a targeted therapy in AML. In addition, CXCR4 could be easily integrated into the initial routine diagnostic work up of AML.
Clinical • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCR4 positive
3years
Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss. (PubMed, Bioact Mater)
The hybrid NPs specifically gathered in the bone marrow and released antagomir-188, which promoted osteogenesis and inhibited adipogenesis of BMSCs and thereby reversed age-related trabecular bone loss and decreased cortical bone porosity in mice. Taken together, this study presents a novel way to obtain bone-targeted exosomes via surface display of CXCR4 and a promising anabolic therapeutic approach for age-related bone loss.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCR4 positive
3years
[VIRTUAL] Tumoral CXCR4 and CXCL12 but not CXCR7 nor PD-L1 expression predicts disease free survival (DFS) and cancer specific survival (CSS) in resected pancreatic adenocarcinoma patients (AACR 2021)
Tumoral CXCR4 and CXCL12 were prognostic factors at the univariate and multivariate analysis as for DFS and CSS in PDAC. Stromal PD-L1 stained perineural infiltration and stromal CXCR4 characterized inflammatory cells in the vascular invasion. Thus tumoral and stromal characterization for CXCR4 and CXCL12 in PDAC is worth to identify prognostic categories and to orient therapeutic approach.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
|
PD-L1 expression • CXCR4 positive
|
PD-L1 IHC 22C3 pharmDx
3years
CXCR4 in Waldenström's Macroglobulinema: chances and challenges. (PubMed, Leukemia)
These data have shed light on the essential role of CXCR4 in this disease and have paved the way to use these findings for predicting treatment response to the Bruton tyrosine kinase (BTK) inhibitor ibrutinib and novel therapeutic approaches in WM, which might be transferable to other related CXCR4 positive diseases. Well known for its central role in cancer progression and distribution, CXCR4 is highlighted in this review with regard to its biology, prognostic and predictive relevance and therapeutic implications in WM.
Review • Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 positive
|
Imbruvica (ibrutinib)
3years
CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. (PubMed, Theranostics)
Furthermore, AMD3100, a specific CXCR4 inhibitor, significantly suppressed HOXB5-mediated CRC metastasis. HOXB5 expression was positively correlated with CXCR4 and ITGB3 expression in human CRC tissues, and patients with positive co-expression of HOXB5/CXCR4, or HOXB5/ITGB3 exhibited the worst prognosis. Our study implicates HOXB5 as a prognostic biomarker in CRC, and defines a CXCL12-HOXB5-CXCR4 positive feedback loop that plays an important role in promoting CRC metastasis.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ETS1 (ETS Proto-Oncogene 1)
|
CXCL12 elevation • CXCR4 positive
|
plerixafor
over3years
Association of CXCR4 Expression and Clinical Outcome in Different Subsets of De Novo Acute Myeloid Leukemia Patients. (PubMed, Clin Lab)
These results suggest that CXCR4 was expressed in a subset of AML patients and was associated with poor prognosis. CXCR4 expression appears to be an independent prognostic factor for survival in a heterogeneous group of AML patients.
Clinical • Clinical data • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCR4 positive
over3years
EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells. (PubMed, J Immunother Cancer)
EBV-EBNA1 promotes chemotactic migration of Treg cells via the TGFβ1-SMAD3-PI3K-AKT-c-JUN-miR-200a-CXCL12-CXCR4 axis in the NPC microenvironment. These results suggest that EBV-EBNA1 may serve as a potential therapeutic target to reshape the NPC microenvironment.
Journal
|
CXCL12 (C-X-C Motif Chemokine Ligand 12) • TGFB1 (Transforming Growth Factor Beta 1) • MIR200A (MicroRNA 200a)
|
CXCR4 positive
over3years
Upregulation of Serine Proteinase Inhibitor Clade B Member 3 (SERPINB3) Expression by Stromal Cell-Derived Factor (SDF-1)/CXCR4/Nuclear Factor kappa B (NF-κB) Promotes Migration and Invasion of Gastric Cancer Cells. (PubMed, Med Sci Monit)
CXCR4-positive patients who also expressed SERPINB3 were inclined to suffer from lymph node metastasis, confirming that SERPINB3 is a downstream molecule of CXCR4. CONCLUSIONS In vitro and pathological results showed that SDF-1/CXCR4 activated the NF-kappaB pathway and upregulated SERPINB3 to facilitate the migration and invasion of gastric cancer cells.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • SERPINB3 (Serpin family B member 3)
|
CXCR4 positive
over3years
[VIRTUAL] Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Final analysis from the Phase 1 single arm trial (SABCS 2020)
A consistent dose response effect for B + E was suggested across all efficacy endpoints for heavily pretreated pts with HER2 negative MBC. When these results are compared with published data for E monotherapy in similar populations, the EC consistently shows numerically greater benefit for all efficacy endpoints 2, 3 . The safety and tolerability of B + E appear comparable to published data on E or B alone, particularly for neutropenia and peripheral neuropathy 1 .
P1 data
|
HER-2 (Human epidermal growth factor receptor 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
HR positive • HER-2 negative • CXCR4 positive
|
Halaven (eribulin mesylate) • balixafortide (POL 6326)
over3years
Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors. (PubMed, Bioconjug Chem)
More importantly, LGCC NPs/DOX significantly suppressed the in vitro and in vivo proliferation of CXCR 4 positive hepatocarcinoma and breast cancer. The findings provide a guideline for the combined application of benzylguanidine and other functional groups in antitumor nanomedicines.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 positive
|
doxorubicin hydrochloride
over3years
Rho GDP-Dissociation Inhibitor 2 Inhibits C-X-C Chemokine Receptor Type 4-Mediated Acute Lymphoblastic Leukemia Cell Migration. (PubMed, Front Oncol)
Therefore, RhoGDI2 may be a brake for CXCR4-positive T-ALL migration. Because migration is a prerequisite for infiltration of leukemia, this work may suggest the possible involvement of RhoGDI2 in infiltration of T-ALL.
Journal
|
ABL1 (ABL proto-oncogene 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCR4 positive